The TL1A-DR3 Axis Selectively Drives Effector Functions in Human MAIT Cells.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 23 04 2019
accepted: 20 09 2019
pubmed: 20 10 2019
medline: 28 5 2020
entrez: 20 10 2019
Statut: ppublish

Résumé

Mucosal-associated invariant T (MAIT) cells are semi-invariant T cells specifically recognizing riboflavin derivatives that are synthesized by many bacteria and fungi presented by MHC class I-related MR1 molecules. Accumulating evidence, however, indicates that MAIT cell functions are inducible by cytokine stimuli in the absence of TCR ligation, identifying MAIT cells as innate sentinels in inflammatory environments. In this study, we demonstrate that death receptor 3 (DR3), a member of the TNFR superfamily, is ex vivo expressed and predominantly upregulated on the surface of human MAIT cells by innate cytokine stimulation. In turn, the DR3 ligand TNF-like protein 1A (TL1A) licenses innate TNF-α production in the absence of cognate triggers, being sufficient to promote activation of primary endothelial cells in vitro. TL1A further amplifies synthesis of IFN-γ and granzyme B in the presence of otherwise weak innate stimuli and strongly augments polyfunctionality. Mechanistically, TL1A potentiates T-bet expression, early NF-κB, and late p38 MAP kinase phosphorylation, with the latter being indispensable for TNF-α production by MAIT cells. Of note, endogenous TL1A is also rapidly released from PBMC cultures in response to bacterial triggering, thereby equally augmenting Ag-specific MAIT cell effector functions. In summary, to our knowledge, we identify a new inflammatory mechanism in MAIT cells linking the DR3/TL1A axis with amplification of TCR-dependent and -independent effector functions, particularly inducing excessive innate TNF-α production. Given that both TL1A and TNF-α are abundantly present at sites of chronic inflammation, the contribution of MAIT cells in such scenarios needs to be determined.

Identifiants

pubmed: 31628153
pii: jimmunol.1900465
doi: 10.4049/jimmunol.1900465
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0
Receptors, Tumor Necrosis Factor, Member 25 0
TNFRSF25 protein, human 0
TNFSF15 protein, human 0
Tumor Necrosis Factor Ligand Superfamily Member 15 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2970-2978

Informations de copyright

Copyright © 2019 by The American Association of Immunologists, Inc.

Auteurs

Arne Sattler (A)

Department for General, Visceral and Vascular Surgery, Charité University Medicine Berlin, 12200 Berlin, Germany; arne.sattler@charite.de.

Lion Gabriel Thiel (LG)

Department for General, Visceral and Vascular Surgery, Charité University Medicine Berlin, 12200 Berlin, Germany.

Annkathrin Helena Ruhm (AH)

Department for General, Visceral and Vascular Surgery, Charité University Medicine Berlin, 12200 Berlin, Germany.

Naima Souidi (N)

BIH Center for Regenerative Therapies (BCRT), Charité University Medicine Berlin, Corporate Member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, 10178 Berlin, Germany.
Institute of Medical Immunology, Charité University Medicine Berlin, Corporate Member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, 13353 Berlin, Germany; and.

Martina Seifert (M)

BIH Center for Regenerative Therapies (BCRT), Charité University Medicine Berlin, Corporate Member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, 10178 Berlin, Germany.
Institute of Medical Immunology, Charité University Medicine Berlin, Corporate Member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, 13353 Berlin, Germany; and.

Gunda Herberth (G)

Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany.

Katja Kotsch (K)

Department for General, Visceral and Vascular Surgery, Charité University Medicine Berlin, 12200 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH